Provided by Tiger Trade Technology Pte. Ltd.

Merck

119.24
-0.1300-0.11%
Volume:2.83M
Turnover:338.63M
Market Cap:295.96B
PE:16.38
High:120.06
Open:119.50
Low:118.66
Close:119.37
52wk High:125.14
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:0.27
T/O Rate:0.11%
Dividend:3.24
Dividend Rate:2.72%
EPS(TTM):7.28
EPS(LYR):7.28
ROE:36.88%
ROA:12.04%
PB:5.63
PE(LYR):16.38

Loading ...

Merck - Jannie Oosthuizen Appointed Executive Vice President & President, Oncology and Msd International

THOMSON REUTERS
·
Feb 23

Merck & Co Inc - Brian Foard Will Join as Executive Vice President and President, Specialty, Pharma & Infectious Diseases, Effective March 2

THOMSON REUTERS
·
Feb 23

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Reuters
·
Feb 23

Merck plans to split human-health business into two divisions, WSJ says

TIPRANKS
·
Feb 23

Merck Shares Rise 1% Premarket After WSJ Reports Co Creates Separate Cancer Business

THOMSON REUTERS
·
Feb 23

BRIEF-Merck Creates Separate Cancer Business As Sales Pressure Looms - WSJ

Reuters
·
Feb 23

Merck Is Splitting Its Pharmaceuticals Unit to Bolster Product Launches Before Its Cancer Drug Keytruda Loses Patent Protection- WSJ

THOMSON REUTERS
·
Feb 23

Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer: What Investors Should Watch

TIPRANKS
·
Feb 21

Merck Initiated at Overweight by Barclays

Dow Jones
·
Feb 20

Barclays Initiates Coverage on Merck With Overweight Rating

MT Newswires Live
·
Feb 20

U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler

Reuters
·
Feb 20

Merck initiated with an Overweight at Barclays

TIPRANKS
·
Feb 20

Is It Too Late To Consider Merck (MRK) After Its Strong Multi Year Share Price Run?

Simply Wall St.
·
Feb 20

Merck Says New Phase 3 Data Indicate Stable Safety Profile for Enflonsia

MT Newswires Live
·
Feb 19

Merck announces new Enflonsia data from SMART trial

TIPRANKS
·
Feb 19

Merck reports positive Phase 3 SMART trial data for ENFLONSIA in high-risk children under 2 across two RSV seasons

Reuters
·
Feb 19

Merck & Co Inc - Smart Trial Data Shows Consistent Safety for Enflonsia

THOMSON REUTERS
·
Feb 19

Merck Announces Positive New Data for Enflonsia™ (Clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (Rsv) Disease Over Two Rsv Seasons

THOMSON REUTERS
·
Feb 19

Merck, Mayo Clinic announce new R&D collaboration

TIPRANKS
·
Feb 18

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

THOMSON REUTERS
·
Feb 18